Search

Pacific Biosciences of California Inc

Затворен

СекторЗдравеопазване

1.14 -11.63

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.1400000000000001

Максимум

1.29

Ключови измерители

By Trading Economics

Приходи

32M

-8.3M

Продажби

-7.5M

37M

EPS

-0.12

Марж на печалбата

-22.258

Служители

485

EBITDA

33M

-5.8M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+83.08% upside

Дивиденти

By Acuity

Следващи печалби

4.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-40M

441M

Предишно отваряне

12.77

Предишно затваряне

1.14

Настроения в новините

By Acuity

50%

50%

156 / 340 Класиране в Healthcare

Pacific Biosciences of California Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.08.2026 г., 23:01 ч. UTC

News

Pacific Biosciences reported lower second-quarter revenue and a wider EPS loss, prompting a reduction in full-year sales guidance. Shares are down in after-market trading.

4.08.2026 г., 21:36 ч. UTC

Pacific Biosciences of California remained roughly flat after market hours. Broader market gains were driven by a decline in crude oil prices.

3.08.2026 г., 23:36 ч. UTC

Pacific Biosciences of California Inc. shares are roughly flat after-market, remaining near the lower end of their one-month trading range.

31.07.2026 г., 19:46 ч. UTC

News
Correlated Moves

Pacific Biosciences of California is trading lower amid a report citing annual sales declines and cash burn concerns impacting its growth outlook.

29.07.2026 г., 16:06 ч. UTC

Correlated Moves

Pacific Biosciences of California Inc shares are lower today, reflecting broader market pressure on small-cap equities and a notable decline in correlated assets.

28.07.2026 г., 16:12 ч. UTC

Pacific Biosciences is trading higher, rebounding from earlier losses despite broader market caution following declines in the Nikkei 225 Index.

27.07.2026 г., 19:06 ч. UTC

Pacific Biosciences is trading higher as the broader market rises, supported by a notable decline in crude oil prices that has eased geopolitical tensions.

24.07.2026 г., 22:31 ч. UTC

Pacific Biosciences shares are higher in after-market trading. No specific company news was identified to explain this movement.

22.07.2026 г., 18:01 ч. UTC

Correlated Moves

Pacific Biosciences of California shares are lower amid broader market pressures and rising crude oil prices, trading below its 20-day moving average.

21.07.2026 г., 13:01 ч. UTC

Pacific Biosciences is rallying in pre-market trading, continuing its upward trend since Monday's close after three sessions of declines. No specific news was identified.

20.07.2026 г., 23:01 ч. UTC

Shares of Pacific Biosciences of California are higher in after-market hours, marking a peak cumulative return since Monday's close amid broader market volatility.

Сравнение с други в отрасъла

Ценова промяна

Pacific Biosciences of California Inc Прогноза

Ценова цел

By TipRanks

83.08% нагоре

12-месечна прогноза

Среден 2.38 USD  83.08%

Висок 3 USD

Нисък 1.5 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Pacific Biosciences of California Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

2

Купи

1

Задържане

1

Продай

Настроение

By Acuity

156 / 340 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat